Opko Health, Inc.
OPK
Positions held
Your positionsOPK isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Opko Health is positioned in the growing diagnostics and research sector, which is critical for advancements in healthcare and has significant long-term potential.
- Revenue increased by 32% compared to the prior quarter, reaching $164 million.
- Gross margin improved to 48.9%, up from 36.8% in the previous quarter.
- The company has a negative profit margin of -12.4%, indicating ongoing financial challenges.
- Net income for 2025 was -225.68 million, reflecting continued losses.
- Operating margin remains negative at -15.3%, despite recent improvements.
Fundamentals
| Market cap | $1.02B | Enterprise value | $1.12B | Trailing P/E | — | Forward P/E | -5.07 |
| PEG | 93.65 | Price / book | 0.86 | Beta | 1.50 | Dividend yield | 0.00% |
| Revenue growth | 4.3% | Earnings growth | — | Gross margin | 19.5% | Operating margin | -15.3% |
| Profit margin | -12.4% | ROE | -5.9% | ROA | -5.5% | Debt / equity | 0.34 |
| Current ratio | 3.35 | Free cash flow | $54.76M | Analyst recommendation | buy | Mean target | $4.38 |
| 52w high | $1.75 | 52w low | $0.98 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $164M | $124M | $148M | $152M | $157M |
| Op margin | -15.3% | -41.1% | -25.8% | -35.3% | -38.3% |
| Net income | -$8.4M | -$54.8M | -$31.3M | $21.6M | -$148M |
| Gross margin | 48.9% | 36.8% | 43.1% | 32.9% | 31.5% |
| Gross profit | $80.0M | $45.8M | $64.0M | $49.9M | $49.4M |
| Operating income | -$25.0M | -$51.0M | -$38.3M | -$53.5M | -$60.0M |
- Revenue +32% vs prior quarter ($164M vs $124M).
- Gross margin 48.9% (was 36.8% prior quarter).
- Operating margin expanded to -15.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $607M | $713M | $863M | $1.0B | — |
| Op margin | -19.3% | -21.3% | -18.2% | -22.5% | — |
| Net income | -$226M | -$53.2M | -$189M | -$328M | — |
| Gross margin | 33.9% | 30.6% | 36.8% | 28.7% | — |
| Gross profit | $206M | $219M | $318M | $288M | — |
| Operating income | -$117M | -$152M | -$157M | -$226M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Bruker Gains 66.3% in a Year: What's Driving the Rally?
2026-10-08 · 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
2026-10-08 · Here's Why You Should Retain WAT Stock in Your Portfolio for Now
2026-10-07 · BDX Expands U.S. Manufacturing With $19B Healthcare Investment
2026-10-07 · Reasons to Add Globus Medical Stock to Your Portfolio Now
2026-10-06 · Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
2026-10-06 · GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal
2026-09-28 · Here's Why You Should Retain OPK Stock in Your Portfolio for Now
2026-09-21 · OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
2026-09-16 · The Bull Case For OPKO Health (OPK) Could Change Following New Mazdutide Royalty-Backed Financing Strategy
2026-09-14 · OPKO Health (OPK) Cashes In A Future Royalty Stream Early
2026-09-11 · OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
Price (daily)
Full chart · RSI · MACD · patterns